4599 Share Price Performance
JP¥0
-316.00 (-100.00%)
Price JP¥0
Share Pricen/a
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
4599 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
StemRIM Key Details
About 4599
- Founded
- 2006
- Employees
- 45
- CEO
- WebsiteView website
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
